US 11,723,874 B2
Delayed release deferiprone tablets and methods of using the same
Bernard Charles Sherman, Toronto (CA); and Michael Spino, Pickering (CA)
Assigned to Chiesi Farmaceutici S.p.A., Parma (IT)
Filed by Chiesi Farmaceutici S.p.A., Parma (IT)
Filed on May 21, 2021, as Appl. No. 17/327,135.
Application 17/327,135 is a continuation of application No. 16/714,520, filed on Dec. 13, 2019, granted, now 11,458,103.
Application 16/714,520 is a continuation of application No. 16/171,170, filed on Oct. 25, 2018, granted, now 10,940,116, issued on Mar. 9, 2021.
Claims priority of provisional application 62/596,043, filed on Dec. 7, 2017.
Claims priority of provisional application 62/577,055, filed on Oct. 25, 2017.
Prior Publication US 2021/0386677 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/28 (2006.01); A61K 9/20 (2006.01); A61K 31/4412 (2006.01); A61K 31/4422 (2006.01); A61P 7/06 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01)
CPC A61K 9/2833 (2013.01) [A61K 9/204 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2072 (2013.01); A61K 9/284 (2013.01); A61K 31/4412 (2013.01); A61K 31/4422 (2013.01); A61P 7/06 (2018.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01)] 27 Claims
 
1. A method for treating transfusional iron overload in a patient with thalassemia syndromes, comprising orally administering to the patient a tablet comprising:
(a) a core comprising (i) about 1000 mg deferiprone, (ii) an enteric polymer in an amount of about 1% to about 5% by weight of the core, (iii) a pH adjusting agent, and (iv) a glidant, and
(b) an enteric coating comprising (i) a plasticizer, (ii) an anti-tacking agent, (iii) an opacifying agent, and (iv) an enteric polymer.